Celcuity Inc.
CELCHeld by 12 specialist biotech funds
High ConvergenceHigh short interest · No specialist buying12 funds opened new positions. Next phase2 readout (Gedatolisib): Jul 2024. Short interest: 27.9% of float.
Held by 12 specialist biotech funds
High ConvergenceHigh short interest · No specialist buying12 funds opened new positions. Next phase2 readout (Gedatolisib): Jul 2024. Short interest: 27.9% of float.
Celcuity Inc., a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, and advanced or metastatic breast cancer. The company is also developing CELsignia MP test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was founded in 2011 and is headquartered in Minneapolis, Minnesota.
Be first to know when this name moves
Fund buys and exits, insider activity, and catalyst alerts across 800+ biotechs — free Monday brief.